Efficacy of Medication in Young Children with Atopic Dermatitis: Study Finds
Advertisement
Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or not they have another inflammatory condition, such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug’s efficacy in children with atopic dermatitis and co-morbid conditions. The study was recently published in the journal Advances in Therapy.
“Dupilumab has proven to be an important treatment for pediatric patients suffering from atopic dermatitis. Our recent research was to help us know if the drug would be as effective in patients with both atopic dermatitis and other common atopic diseases that could add to the inflammatory burden,” said Mark Boguniewicz, MD, pediatric allergist and immunologist at National Jewish Health and lead author on the study.
“With this illness, the quality of life of our patients and their families is negatively impacted, and this takes a toll on school or job performance and social interactions,” said Dr. Boguniewicz
For the study, investigators evaluated children aged 6 months to 5 years with moderate-to-severe atopic dermatitis who had been treated with either dupilumab or a placebo. Researchers compared patients who had only atopic dermatitis to those who had atopic dermatitis plus additional “type 2” inflammatory diseases, such as asthma and allergies. Results showed that dupilumab improved atopic dermatitis signs and symptoms in both groups of patients.
“Many children suffer from multiple allergic conditions at the same time, so knowing that dupilumab can be used to safely and effectively treat their atopic dermatitis whether or not they have additional atopic diseases such as asthma or allergies is an important step forward,” explained Dr. Boguniewicz.
Reference: Boguniewicz, M., Sher, L.D., Paller, A.S. et al. Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type 2 Comorbidities. Adv Ther 41, 4601–4616 (2024). https://doi.org/10.1007/s12325-024-02998-4
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.